NYSTATIN AND TRIAMCINOLONE ACETONIDE
Post-LOEnystatin and triamcinolone acetonide
ANDATOPICALOINTMENT
Approved
Aug 2021
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
NYSTATIN AND TRIAMCINOLONE ACETONIDE (nystatin and triamcinolone acetonide) by Ichnos Glenmark Innovation is corticosteroid hormone receptor agonists [moa]. First approved in 2021.
Drug data last refreshed 18h ago
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Polyene Antifungal
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on NYSTATIN AND TRIAMCINOLONE ACETONIDE at Ichnos Glenmark Innovation? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.